Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™
April 27 2022 - 04:30PM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company with the mission to improve patient outcomes by providing
personalized insights that inform critical decisions throughout the
patient care journey, announced today that it plans to present new
data from ongoing clinical research evaluating the utility of
DetermaIO™ at the upcoming American Society of Clinical Oncology
Annual Meeting (ASCO), taking place June 3-7, 2022 virtually and
in-person in Chicago.
Following are details of the three Oncocyte abstracts that have
been accepted for poster presentations at the 2022 ASCO Annual
Congress:
- Title: An
immune-related gene expression profile to predict the efficacy of
adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in
metastatic colorectal cancer: A translational analysis of the phase
II randomized AtezoTRIBE studyAuthors: Boccaccino,
A., et al.Session Title: Gastrointestinal Cancer – Colorectal
and AnalSession Date & Time: Saturday, June 4, 2022, 8:00
AM-11:00 AM CDTAbstract #: 3581
- Title: The
27-gene IO score is associated with molecular features and response
to immune checkpoint inhibitors (ICI) treatment in patients with
gastric cancerAuthors: Varga, M., et al. Session
Title: Gastrointestinal Cancer – Gastroesophageal, Pancreatic,
and HepatobiliarySession Date & Time: Saturday, June 4, 2022,
8:00 AM-11:00 AM CDTAbstract #: 4058
- Title:
Association of 27-gene IO immune score with outcome in a
phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in
metastatic triple negative breast cancer
(mTNBC)Authors: Page, D., et al.Session Title:
Breast Cancer – MetastaticSession Date & Time: Monday,
June 6, 2022, 8:00 AM-11:00AM CDTAbstract #: 1082
The ASCO 2022 virtual program and abstracts are currently
available online at the ASCO 2022 website. Oncocyte will be
distributing a data press release on May 26, 2022, summarizing the
results of the posters and the implications for DetermaIO.
In addition, Oncocyte is supporting a Continuing Medical
Education Event (CME) by way of an unrestricted educational grant
on June 5, 2022, at 6:30PM CDT. The program, entitled Convergence
of Molecular Diagnostics and Tumor Microenvironment to Improve
Personalized Medicine in Breast, Lung, and Colorectal Cancers, will
be chaired by David Gandara, MD (UC Davis Comprehensive Cancer
Center). Charu Aggarwal, MD, MPH (Abramson Cancer Center,
University of Pennsylvania), Heinz-Josef Lenz, MD (USC Norris
Comprehensive Cancer Center), and Priyanka Sharma, MD (University
of Kansas Medical Center) will comprise the faculty.
This 90-minute session, held adjunct to the 2022 ASCO Annual
Meeting, will offer updates on the latest advances in molecular
diagnostic tools and biomarkers to help guide personalized
therapies and predict which patients will have the best outcomes.
Novel diagnostic tools have the potential to enhance treatment
decision-making, optimize immunotherapy selection, and ultimately
improve patient care.
Disclaimer: Not an official event of the 2022 ASCO Annual
Meeting. Not sponsored, endorsed, or accredited by ASCO®,
CancerLinQ®, or Conquer Cancer® the ASCO Foundation.
Oncocyte’s DetermaIO test is a precision diagnostic designed to
determine the likelihood of benefit of immune checkpoint
inhibitors, and is the first and only test to measure the entire
tumor immune microenvironment (TIME). By evaluating the entire
TIME, the test can help identify patients that are primed to
respond to immunotherapy as well as patients who may not respond as
well, allowing for physicians and their patients to make informed
decisions about their treatment journey.
About OncocyteOncocyte is a precision
diagnostics and monitoring company with the mission to improve
patient outcomes by providing clear insights that inform critical
decisions in the diagnosis, treatment, and monitoring of cancer.
The Company, through its proprietary tests and pharmaceutical
services business, aims to help save lives by accelerating the
diagnosis of cancer and advancing cancer care. The Company’s tests
are designed to help provide clarity and confidence to physicians
and their patients at every stage post-diagnosis treatment.
DetermaRx™ identifies early-stage lung cancer patients who are at
high risk for cancer recurrence and who may benefit from adjuvant
chemotherapy. DetermaIO™, a gene expression test currently used as
a research-use only tool, assesses the tumor microenvironment to
predict response to immunotherapies. The Company’s pipeline of
tests in development also includes DetermaTx™, which will assess
mutational status of a tumor, blood-based test DetermaCNI™, which
can monitor cancer patients for recurrence of disease, long-term
recurrence monitoring test DetermaMx™, and blood-based solid organ
transplantation monitoring test TheraSureTM. In addition,
Oncocyte’s pharmaceutical services provide companies that are
developing new cancer treatments a full suite of molecular testing
services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and
TheraSure™ are trademarks of Oncocyte Corporation.
Investor Contact
Caroline CornerICR Westwicke Tel:
415.202.5678caroline.corner@westwicke.com
Media Contact
Megan KernanICR Westwicke Healthcare
PRTel: 646.677.1870megan.kernan@westwicke.com
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Mar 2023 to Mar 2024